Tyr794
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.2
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr794  -  VEGFR1 (human)

Site Information
SSEIKTDyLSIIMDP   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 455807

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 ) , mutation of modification site ( 2 , 3 ) , phospho-antibody ( 2 ) , western blotting ( 2 )
Relevant cell line - cell type - tissue:

Downstream Regulation
Effects of modification on VEGFR1:
phosphorylation ( 2 )
Effects of modification on biological processes:
cell cycle regulation ( 3 ) , cell differentiation, altered ( 2 )

References 

1

Moritz A (2007) CST Curation Set: 2507; Year: 2007; Biosample/Treatment: cell line, K562/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

2

Ahmad S, et al. (2006) Direct evidence for endothelial vascular endothelial growth factor receptor-1 function in nitric oxide-mediated angiogenesis. Circ Res 99, 715-22
16946136   Curated Info

3

Zeng H, Dvorak HF, Mukhopadhyay D (2001) Vascular permeability factor (VPF)/vascular endothelial growth factor (VEGF) peceptor-1 down-modulates VPF/VEGF receptor-2-mediated endothelial cell proliferation, but not migration, through phosphatidylinositol 3-kinase-dependent pathways. J Biol Chem 276, 26969-79
11350975   Curated Info